Healthcare

September 18, 2014

1

Diabetes: Tizi Ouzou plant to start production of new drug in 2015

The Oued Aissi Plant (Tizi Ouzou), coming under Novo Nordisk laboratories will start production of new drug for diabetes patients in 2015, unveiled Wednesday in Vienna (Austria), new CEO of Novo Nordisk Algeria, Peter Ulvskjold.


The Oued Aissi plant which produces Metformine as part of the Algerian-Danish Partnership will start soon the production of NovoNorm, Ulvskjold"...

Continue Reading >

September 17, 2014

2

Health bill prohibits tobacco, alcohol beverage sales to minors

The bill relating to health bans the sale of tobacco and alcoholic drink to minors and all forms of advertisements for such products.


In chapter IV on health problems, especially great social scourges, the bill notes in Article 93 that "sales of tobacco and tobacco products to minors are prohibited."


"...

Continue Reading >

September 16, 2014

3

200 Algerian diabetes specialists at EASD conference in Vienna

Nearly 200 Algerian diabetes specialists are taking part in the 50th session of the European Association for the Study of Diabetes (EASD), opened Monday in Vienna, Austria.


Specialists from all around the world are participating in this annual event to shed light on the latest scientific developments in relation to diabetes.


"...

Continue Reading >

September 16, 2014

4

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction in Blood Glucose in Phase III Study

Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were previously untreated. Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination tablet.


...

Continue Reading >

September 9, 2014

5

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

  • 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance®
  • Abstracts on investigational empagliflozin/linagliptin combination tablet
  • Data on Lilly/BI’s investigational insulin glargine product
  • Abstracts on Trajenta® (linagliptin) and linagliptin in combination with metformin

Data to be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria,"...

Continue Reading >

September 8, 2014

6

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

  • Data show Spiriva® Respimat® reduced the risk of patients having a severe asthma exacerbation** by 21% when used as add-on therapy in patients who have symptoms despite taking current standard treatment†1
  • Almost one in two patients with asthma still experience symptoms while receiving current treatment options,2,3,4 putting them at increased risk of potentially life-threatening asthma exacerbations5
  • The regulatory acceptance of Spiriva® Respimat® in asthma establishes a new class of treatment – no new inhaled treatment class has been approved...

    Continue Reading >

September 8, 2014

7

TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

European Respiratory Society International Congress 2014

  • First presentation of TONADO™ results for the only fixed-dose combination (FDC) containing tiotropium
  • Pivotal Phase III studies for tiotropium + olodaterol Respimat® FDC met lung function and quality of life primary endpoints†,1
  • Data support recent regulatory submissions in Europe and US for tiotropium + olodaterol Respimat® FDC

For media outside"...

Continue Reading >

September 4, 2014

8

Jobless youth anger: 160 detained workers suffer inside an oil base Southern Algeria

Over 160 workers, who have been detained since more than a week in their company "Inavor" National Petroleum, one of the branches of SONATRACH, in the region called Tinezeroufat, which is located 200 kilometers from the headquarters of Regguane Department in the state of Adrar, while angry youth in the region in question refuse to leave the building that is besieged by security services until now, according to workers' explanations for Echorouk.


"...

Continue Reading >

September 2, 2014

9

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

  • RE-LY® sub-analysis shows that Pradaxa® treatment favourably affects kidney function1 deterioration over time compared to warfarin
  • Data provide additional support for long-term use of Pradaxa® in stroke prevention in non-valvular atrial fibrillation (NVAF)1

Non-US/Non-UK/Non-Canadian Media

New data presented today indicate that kidney function decline is less pronounced in patients with an irregular heartbeat (non-valvular"...

Continue Reading >

September 1, 2014

10

Boehringer Ingelheim to Present Comprehensive Data Supporting Broad Respiratory Portfolio in COPD, Asthma and IPF at ERS 2014

  • First presentation of positive results from pivotal, Phase III TONADO™ studies that supported recent regulatory submissions in Europe and US for tiotropium + olodaterol Respimat®*in COPD - the only fixed-dose combination (FDC) containing tiotropium
  • Data further confirming role of Spiriva® in delivering long-term benefits to COPD patients and in helping to establish COPD management strategy
  • Pooled Phase III data from large UniTinA-asthma® clinical trial programme showing improvement in both symptom control and risk of exacerbations across asthma severities...

    Continue Reading >